A new tool developed by Johns Hopkins researchers estimates that the 2025 measles outbreak in the U.S. carried an economic cost of more than $37 million.
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.